First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for…
<!-- Name:DistributionId Value:8809173 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Kinnate Biopharma
Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF…
<!-- Name:DistributionId Value:8788450 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug…
<!-- Name:DistributionId Value:8749251 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR…
SAN FRANCISCO and SAN DIEGO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced the poster…
Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug…
SAN FRANCISCO and SAN DIEGO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the…
Kinnate Biopharma Inc. to Participate in the 2022 Wells Fargo Securities Healthcare…
SAN FRANCISCO and SAN DIEGO, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its…
Kinnate Biopharma Inc. to Participate in the 2022 Wedbush PacGrow Healthcare Virtual…
SAN FRANCISCO and SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its…
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
SAN FRANCISCO and SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the…
Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product…
SAN FRANCISCO and SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of…
Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of its…
SAN FRANCISCO and SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of…